Cutaneous localized annular chromoblastomycosis

• Published in: Journal of cutaneous pathology Vol. 36; no. 2; pp. 257 - 261
• Main Authors: Salgado, Claudio G., Da Silva, Moises B., Yamano, Suellen S. P., Salgado, Ubirajara I., Diniz, José A. P., Da Silva, Jorge P.
• Format: Journal Article
• Language: English
• Published: Oxford, UK Blackwell Publishing Ltd 01.02.2009; Wiley-Blackwell
• Subjects: Administration, Cutaneous; Antifungal Agents - pharmacology; Ascomycota; Biological and medical sciences; Chromoblastomycoses; Chromoblastomycosis - drug therapy; Chromoblastomycosis - microbiology; Chromoblastomycosis - pathology; Dermatology; Fonsecaea pedrosoi; Human mycoses; Humans; Infectious diseases; Itraconazole - pharmacology; Male; Medical sciences; Middle Aged; Mitosporic Fungi; Mycoses; Tropical mycoses; Infection; Skin disease; Anatomic pathology; Mycosis; Dermatology; Chromoblastomycosis; Skin; Localized
• DOI: 10.1111/j.1600-0560.2008.01025.x
• ISSN: 0303-6987

Chromoblastomycosis (CBM) is a difficult‐to‐treat dermal mycosis characterized by the presence of round, pigmented, sclerotic bodies formed by black fungi found in polymorphic lesions. According to the morphology of a lesion, different clinical types of the disease have been described. We present three patients who each developed a single, 10‐cm diameter, 8 to 15‐year‐old, well‐circumscribed, slow‐growing, annular, papulosquamous or papulosquamous‐verrucous lesion, with no regression despite the use of topical antifungals. Skin scrapings and biopsies confirmed CBM and microculture defined the agent as Fonsecaea pedrosoi. The patients were treated with 200 mg/day of itraconazole for 6–9 months and were discharged after complete regression of the lesions. All were examined after the first and second year of the end of treatment and there were no signs of recurrence. A new clinical type of CBM is described, and itraconazole appears to be effective and safe in curing these patients after no more than 9 months of therapy.